Cabozantinib Ipsen 20 mg film-coated tablets

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, Leids Universitair Medisch Centrum (LUMC), Centro Di Riferimento Oncologico Di Aviano

Conditions

Renal Cell CarcinomaRenal cell carcinomRenal cell carcinoma

Phase 2

SKIPP2: Cabozantinib Dose Skipping as an Alternative to Dose Reductions

Not yet recruitingCTIS2025-522962-58-00

Leids Universitair Medisch Centrum (LUMC)Renal cell carcinom

Target: 34Updated: 2025-11-10

Phase 3

A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants with Advanced RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)

RecruitingCTIS2024-517136-21-00

Merck Sharp & Dohme LLCRenal Cell Carcinoma

Start: 2025-12-05Target: 398Updated: 2025-11-17

Phase 4

Intensified Monitoring of PhArmacology of Cabozantinib as a tool for Toxicity management in patients with renal cell carcinoma

Not yet recruitingCTIS2026-525267-40-00

Centro Di Riferimento Oncologico Di AvianoRenal cell carcinoma

Target: 216Updated: 2026-05-21